SG11201706050WA - Substituted nucleoside derivatives useful as anticancer agents - Google Patents

Substituted nucleoside derivatives useful as anticancer agents

Info

Publication number: SG11201706050WA
Authority: SG; Singapore
Prior art keywords: anticancer agents; derivatives useful; substituted nucleoside; nucleoside derivatives; substituted
Prior art date: 2015-02-24

Application number

SG11201706050WA

Inventor

John Howard Tatlock

Indrawan James Mcalpine

Michelle Bich Tran-Dube

Eugene Yuanjin Rui

Martin James Wythes

Robert Arnold Kumpf

Michele Ann Mctigue

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-24

Filing date

2016-02-15

Publication date

2017-09-28

2016-02-15 Application filed by Pfizer filed Critical Pfizer

2017-09-28 Publication of SG11201706050WA publication Critical patent/SG11201706050WA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG11201706050WA 2015-02-24 2016-02-15 Substituted nucleoside derivatives useful as anticancer agents SG11201706050WA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562119932P	2015-02-24	2015-02-24
US201562213801P	2015-09-03	2015-09-03
US201662279209P	2016-01-15	2016-01-15
PCT/IB2016/050803 WO2016135582A1 (en)	2015-02-24	2016-02-15	Substituted nucleoside derivatives useful as anticancer agents

Publications (1)

Publication Number	Publication Date
SG11201706050WA true SG11201706050WA (en)	2017-09-28

Family

ID=55451515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201706050WA SG11201706050WA (en)	2015-02-24	2016-02-15	Substituted nucleoside derivatives useful as anticancer agents

Country Status (29)

Country	Link
US (1)	US10428104B2 (en)
EP (1)	EP3262057B1 (en)
JP (1)	JP6584521B2 (en)
KR (1)	KR20170119705A (en)
CN (1)	CN107278205A (en)
AU (2)	AU2016225133B2 (en)
BR (1)	BR112017017396A2 (en)
CA (1)	CA2921314A1 (en)
CL (1)	CL2017002155A1 (en)
CO (1)	CO2017008403A2 (en)
CR (1)	CR20170384A (en)
CU (1)	CU20170105A7 (en)
DO (1)	DOP2017000195A (en)
EA (1)	EA031895B1 (en)
ES (1)	ES2792899T3 (en)
GT (1)	GT201700189A (en)
IL (1)	IL253637A0 (en)
MX (1)	MX2017010844A (en)
NI (1)	NI201700095A (en)
PE (1)	PE20171449A1 (en)
PH (1)	PH12017501413A1 (en)
SG (1)	SG11201706050WA (en)
SV (1)	SV2017005514A (en)
TN (1)	TN2017000357A1 (en)
TW (1)	TWI622595B (en)
UA (1)	UA118315C2 (en)
UY (1)	UY36564A (en)
WO (1)	WO2016135582A1 (en)
ZA (1)	ZA201705092B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR104326A1 (en) *	2015-05-04	2017-07-12	Lilly Co Eli	5-SUBSTITUTED NUCLEOSID COMPOUNDS
TWI730980B (en)	2015-08-26	2021-06-21	比利時商健生藥品公司	Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
MA43671A (en) *	2016-03-10	2018-11-28	Janssen Pharmaceutica Nv	ANALOGUES OF SUBSTITUTED NUCLEOSIDES FOR USE AS PRMT5 INHIBITORS
KR20180116307A (en)	2016-03-10	2018-10-24	얀센 파마슈티카 엔.브이.	Substituted nucleoside analogs for use as PRMT5 inhibitors
AU2017326485B2 (en)	2016-09-14	2021-04-22	Janssen Pharmaceutica Nv	Fused bicyclic inhibitors of menin-MLL interaction
SI3512857T1 (en)	2016-09-14	2021-07-30	Janssen Pharmaceutica Nv	Spiro bicyclic inhibitors of menin-mll interaction
US12084462B2 (en)	2016-09-14	2024-09-10	Janssen Pharmaceutica Nv	Spiro bicyclic inhibitors of menin-MLL interaction
UA124074C2 (en) *	2016-10-03	2021-07-14	Янссен Фармацевтика Нв	Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX2019007067A (en)	2016-12-15	2019-10-15	Janssen Pharmaceutica Nv	Azepane inhibitors of menin-mll interaction.
US11220524B2 (en) *	2017-02-20	2022-01-11	Prelude Therapeutics Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
WO2018152501A1 (en) *	2017-02-20	2018-08-23	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (en)	2017-02-24	2019-09-30	Янссен Фармацевтика Нв	NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS
UA127679C2 (en)	2017-02-27	2023-11-29	Янссен Фармацевтика Нв	Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018160855A1 (en)	2017-03-01	2018-09-07	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
KR20200036922A (en) *	2017-08-09	2020-04-07	프렐루드 테라퓨틱스, 인코포레이티드	Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
WO2019084470A1 (en) *	2017-10-26	2019-05-02	Prelude Therapeutics, Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CN111479817B (en)	2017-12-08	2023-03-21	詹森药业有限公司	Spirobicyclic analogs
ES2927860T3 (en)	2017-12-13	2022-11-11	Lupin Ltd	Substituted Bicyclic Heterocyclic Compounds as PRMT5 Inhibitors
US11396517B1 (en)	2017-12-20	2022-07-26	Janssen Pharmaceutica Nv	Exo-aza spiro inhibitors of menin-MLL interaction
US10711007B2 (en)	2018-03-14	2020-07-14	Prelude Therapeutics Incorporated	Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
BR112020018636A2 (en) *	2018-03-14	2020-12-29	Prelude Therapeutics, Incorporated	SELECTIVE ARGININE METHYLTRANSPHERASE 5 (PRMT5) INHIBITORS
EP3833669A4 (en) *	2018-08-07	2022-05-11	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
JP2022521491A (en) *	2019-02-13	2022-04-08	プレリュード・セラピューティクス・インコーポレイテッド	Selective inhibitor of protein arginine methyltransferase 5 (PRMT5)
JP2022521818A (en) *	2019-03-25	2022-04-12	カリフォルニアインスティチュートオブテクノロジー	PRMT5 inhibitor and its use
TW202112375A (en)	2019-06-06	2021-04-01	比利時商健生藥品公司	Methods of treating cancer using prmt5 inhibitors
DK3980417T3 (en)	2019-06-10	2023-12-18	Lupin Ltd	PRMT5-Inhibitorer
IL288741B1 (en)	2019-06-12	2024-11-01	Janssen Pharmaceutica Nv	Novel spirobicyclic intermediates
GEP20247638B (en)	2019-10-22	2024-07-10	Lupin Ltd	Pharmaceutical combination of prmt5 inhibitors
EP4069698A1 (en)	2019-12-03	2022-10-12	Lupin Limited	Substituted nucleoside analogs as prmt5 inhibitors
WO2022040172A1 (en)	2020-08-18	2022-02-24	Incyte Corporation	Process and intermediates for preparing a jak1 inhibitor
MX2023002037A (en)	2020-08-18	2023-06-12	Incyte Corp	Process and intermediates for preparing a jak inhibitor.
US20240101589A1 (en) *	2020-10-08	2024-03-28	Strom Therapeutics Limited	Inhibitors of mettl3
CN112679505B (en) *	2020-12-25	2022-04-22	杭州澳赛诺生物科技有限公司	Synthesis method of 4-methyl-7H-pyrrolo [2,3-d ] pyrimidine
WO2022153161A1 (en)	2021-01-14	2022-07-21	Pfizer Inc.	Treatment of cancer using a prmt5 inhibitor
CN118317946A (en)	2021-07-12	2024-07-09	因赛特公司	Processes and intermediates for the preparation of baratinib
WO2023017152A1 (en) *	2021-08-13	2023-02-16	Albert-Ludwigs-Universität Freiburg	Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
WO2024170488A1 (en)	2023-02-13	2024-08-22	Astrazeneca Ab	Prmt5 inhibitor for use in cancer therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5864033A (en) *	1989-09-15	1999-01-26	Metabasis Therapeutics, Inc.	Adenosine kinase inhibitors
US5646128A (en) *	1989-09-15	1997-07-08	Gensia, Inc.	Methods for treating adenosine kinase related conditions
US5795977A (en) *	1989-09-15	1998-08-18	Metabasis Therapeutics, Inc.	Water soluble adenosine kinase inhibitors
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en)	1990-01-23	1999-01-15	.	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB9813554D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
US6831069B2 (en) *	1999-08-27	2004-12-14	Ribapharm Inc.	Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2004016635A2 (en) *	2002-08-15	2004-02-26	Cv Therapeutics, Inc.	Partial and full agonists of a1 adenosine receptors
EA201190178A1 (en) *	2009-03-20	2012-06-29	Алиос Биофарма, Инк.	REPLACED NUCLEOSIDE AND NUCLEOTIC ANALOGUES
US20120077814A1 (en)	2010-09-10	2012-03-29	Zhong Wang	Sulfonamide, sulfamate, and sulfamothioate derivatives
US9416154B2 (en) *	2011-07-13	2016-08-16	Merck Sharp & Dohme Corp.	5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8575119B2 (en) *	2011-09-23	2013-11-05	Enanta Pharmaceuticals, Inc.	2′-chloroacetylenyl substituted nucleoside derivatives
WO2015200680A2 (en) *	2014-06-25	2015-12-30	Epizyme, Inc.	Prmt5 inhibitors and uses thereof
AR104326A1 (en) *	2015-05-04	2017-07-12	Lilly Co Eli	5-SUBSTITUTED NUCLEOSID COMPOUNDS
US9708359B2 (en) *	2015-08-06	2017-07-18	Chimerix, Inc.	Pyrrolopyrimidine nucleosides and analogs thereof

2016
- 2016-02-15 UA UAA201708102A patent/UA118315C2/en unknown
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/en unknown
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/en not_active Application Discontinuation
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/en active Pending
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-15 EA EA201791563A patent/EA031895B1/en not_active IP Right Cessation
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/en unknown
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/en unknown
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/en not_active Application Discontinuation
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/en not_active Expired - Fee Related
- 2016-02-15 ES ES16707209T patent/ES2792899T3/en active Active
- 2016-02-15 CR CR20170384A patent/CR20170384A/en unknown
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en active Application Filing
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 TW TW105104968A patent/TWI622595B/en not_active IP Right Cessation
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-22 UY UY0001036564A patent/UY36564A/en not_active Application Discontinuation
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/en unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/en unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/en unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/en unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/en unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/en unknown
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112017017396A2 (en)	2018-04-03
TWI622595B (en)	2018-05-01
US10428104B2 (en)	2019-10-01
PH12017501413A1 (en)	2018-01-29
CU20170105A7 (en)	2017-10-05
PE20171449A1 (en)	2017-10-02
CR20170384A (en)	2017-11-16
TN2017000357A1 (en)	2019-01-16
EA201791563A1 (en)	2018-01-31
AU2016225133B2 (en)	2018-11-29
EA031895B1 (en)	2019-03-29
SV2017005514A (en)	2018-04-11
AU2018278842A1 (en)	2019-01-03
EP3262057B1 (en)	2020-04-15
CO2017008403A2 (en)	2017-10-31
ES2792899T3 (en)	2020-11-12
DOP2017000195A (en)	2017-10-15
IL253637A0 (en)	2017-09-28
GT201700189A (en)	2019-06-10
CA2921314A1 (en)	2016-08-24
TW201643176A (en)	2016-12-16
CL2017002155A1 (en)	2018-05-11
MX2017010844A (en)	2017-12-07
UY36564A (en)	2016-09-30
US20160244475A1 (en)	2016-08-25
UA118315C2 (en)	2018-12-26
KR20170119705A (en)	2017-10-27
EP3262057A1 (en)	2018-01-03
ZA201705092B (en)	2019-06-26
NI201700095A (en)	2017-10-31
JP6584521B2 (en)	2019-10-02
AU2016225133A1 (en)	2017-08-10
JP2018510850A (en)	2018-04-19
WO2016135582A1 (en)	2016-09-01
CN107278205A (en)	2017-10-20

Publication	Publication Date	Title
ZA201705092B (en)	2019-06-26	Substituted nucleoside derivatives useful as anticancer agents
IL282167A (en)	2021-05-31	Substituted carbonucleoside derivatives useful as anticancer agents
HK1255045A1 (en)	2019-08-02	Substituted oxopyridine derivatives
HK1250959A1 (en)	2019-01-18	Nitrobenzyl derivatives of anti-cancer agents
IL263121B (en)	2021-10-31	Phosphoramidate nucleoside derivatives as anticancer agents
IL253381A0 (en)	2017-09-28	9h-pyrrolo-dipyridine derivatives
HK1245258A1 (en)	2018-08-24	New difluoroketamide derivatives
IL249581A0 (en)	2017-02-28	Isoindolinone derivatives useful as antiviral agents
GB201703369D0 (en)	2017-04-19	Antiviral composition
EP3515904C0 (en)	2024-01-17	Benzoimidazole derivatives as anticancer agents
IL251005B (en)	2020-03-31	Pyrido-oxazinone derivatives
HK1246790A1 (en)	2018-09-14	Ethynyl derivatives
HK1253336A1 (en)	2019-06-14	Indolotryptoline anticancer agents
HK1249096A1 (en)	2018-10-26	Ethynyl derivatives
PT3319956T (en)	2021-03-29	Substituted oxopyridine derivatives